Nasal Polyps

The AJMC® Nasal Polyps compendium is a comprehensive resource for clinical news and expert insights for the condition, which is caused by chronic inflammation.

Further Study Needed to Evaluate Olfaction Recovery in CRSwNP

August 3rd 2022, 6:04pm

Article

This new study evaluated outcomes following add-on dupilumab to treat severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP).

Researchers Find Strong Overlap of Upper Airway Diseases

July 28th 2022, 6:47pm

Article

There was also an association between outpatient visit burden and comorbidities and the number of inflammatory upper airway diseases.

Novel Model Appears Effective at Predicting ECRSwNP

July 20th 2022, 5:34pm

Article

This new study investigated the ability of a multiparametric model to calculate risk of eosinophilic chronic rhinosinusitis with nasal polyps (ECRSwNP) by comparing its clinical characteristics with noneosinophilic CRSwNP.

Calprotectin’s Role as Biomarker in CRSwNP Investigated in Italian Study

July 14th 2022, 1:21pm

Article

Conflicting prior study results on the effectiveness of calprotectin expression as a protective or pathologic response among persons with chronic rhinosinusitis with nasal polyps (CRSwNP) spurred this new investigation.

Dupilumab Safe, Effective Among Patients With Comorbid Asthma, CRSwNP

July 11th 2022, 10:46pm

Article

Although approved for use among patients with severe or refractory asthma, few studies have investigated its effectiveness among patients with comorbid mild to moderate asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).

Certain Factors May Reduce ESS-Induced Smell Improvement in CRSwNP

July 9th 2022, 4:20pm

Article

Endoscopic sinus surgery was associated with improvement in self-reported olfactory function among patients with chronic rhinosinusitis with nasal polyps (CRSwNP), in which a longer CRSwNP disease course and higher blood eosinophilia were cited as risk factors linked with poor sense of smell recovery.

Dupilumab Demonstrates Safety, Efficacy Across Several Type 2 Inflammatory Diseases

July 2nd 2022, 10:01pm

Article

Research presented at the European Academy of Allergy and Clinical Immunology Annual Congress show the safety and efficacy of dupilumab across several progressive diseases with underlying type 2 inflammation, including eosinophilic esophagitis (EoE), severe asthma, and severe chronic rhinosinusitis with nasal polyps.

Self-administration of Biologics Well Tolerated, Effective for Asthma and CRS With Nasal Polyps

June 22nd 2022, 1:00pm

Article

The adequate safety and improved symptom burden observed with self-administration of biologic therapies at home for the management of severe asthma and chronic rhinosinusitis with nasal polyps suggests potential in shifting care away from the more costlier in-patient setting.

Nasal Polyps in CRS Found to Influence Risk of Past, Current Proton Pump Inhibitor Use

June 16th 2022, 3:15pm

Article

Incidence of chronic rhinosinusitis (CRS) was associated with a higher rate of current and past proton pump inhibitor (PPI) use, in which elevated risk of PPI use and prescription duration were only found in those with CRS who did not have nasal polyps.

Symptom Burden, QOL in CRSwNP Significantly Improved With Novel Fluticasone Delivery System

June 14th 2022, 6:20pm

Article

Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who are surgery-naive or whose symptoms recur after endoscopic sinus surgery exhibited similarly significant benefits in quality of life (QOL) and symptom burden when given an exhalation system with fluticasone.